Overview

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.